Last updated on April 17, 2014 at 21:23 EDT

ExAblate Receives Approval of Health Canada for the Treatment of Uterine Fibroids and Pain Palliation of Bone Metastases

August 22, 2013

Third generation ExAblate system, using non-invasive MR guided Focused Ultrasound (MRgFUS) now available for Canadian patients

TIRAT CARMEL, Israel, August 22, 2013 /PRNewswire/ –

InSightec Ltd, the leader in MR guided Focused Ultrasound therapy, announced that its
ExAblate system received approval of Health Canada for MRgFUS treatment of uterine
fibroids and for pain palliation of bone metastases.

ExAblate combines high intensity focused ultrasound waves and continuous MRI guidance
and monitoring. The focused ultrasound energy is used to heat and destroy the targeted
tissue while the MR images are used to guide the energy beam and monitor treatment
outcome. ExAblate’s main benefits are that in a single session with this non-ionizing
radiation, the treatment allows patients a rapid recovery while minimizing morbidity and
trauma with a high safety profile, thus improving patients’ quality of life.

Health Canada’s approval was based on data published from clinical trials conducted in
Canada, the USA and Europe. ExAblate received the first approval by the United States FDA
in 2004 and is the only MR guided Focused Ultrasound system to have both FDA and Health
Canada’s approval. Ten thousand patients globally have already been treated with ExAblate.

Dr. Kobi Vortman, CEO and founder of InSightec, said, “Health Canada’s approval is
another vote of confidence in ExAblate’s high safety profile and excellent outcomes. It
once again highlights InSightec’s firm commitment to expand clinical indications in
gynecology as well as in oncology and neurosurgery.”

About InSightec

InSightec Ltd. is privately held by Elbit Imaging, General Electric, and MediTech
Advisors. Founded in 1999 InSightec developed ExAblate to transform MRI-guided Focused
Ultrasound (MRgFUS) into a clinically viable technology. ExAblate has won several awards
for innovation and its potential to help mankind including The Wall Street Journal
Technology Innovation Awards and the European Union’s IST grand prize. TIME magazine
recently named Focused Ultrasound as “one of 50 best inventions.” For more information
please visit: http://US.InSightec.com.

        Media Contact:

        Lynn Golumbic
        Tel: +972-4-8131309

SOURCE InSightec Ltd

Source: PR Newswire